PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHaleon Regulatory News (HLN)

Share Price Information for Haleon (HLN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 329.00
Bid: 329.20
Ask: 329.40
Change: -3.40 (-1.02%)
Spread: 0.20 (0.061%)
Open: 328.00
High: 332.10
Low: 326.80
Prev. Close: 332.40
HLN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of Haleon 2023 Annual General Meeting

20 Apr 2023 17:30

RNS Number : 9729W
Haleon PLC
20 April 2023
 

 

 

Haleon plc: Results of Haleon 2023 Annual General Meeting

 

20 April 2023: Haleon plc (the "Company") (LSE/NYSE: HLN) today announces that the following resolutions were decided by poll vote at the Company's 2023 Annual General Meeting ("AGM") which was held today.

 

Resolutions 20, 21, 22, 26, 27 and 28 were passed as special resolutions; all other resolutions were passed as ordinary resolutions. Full text of the resolutions is contained in the Company's Notice of AGM, which is available at www.haleon.com.

 

Haleon plc - Poll Results by All Shareholders

 

Resolution

Votes For

For (% of shares voted)

Votes Against

Against (% of shares voted)

Total Votes Cast (excluding withheld)

% of issued share capital voted1

Votes Withheld2

1

To receive the Annual Report and Accounts

7,888,244,555

99.97

2,091,612

0.03

7,890,336,167

85.44

15,542,626

2

To approve the Directors' Remuneration Report

7,769,899,285

98.72

101,062,356

1.28

7,870,961,641

85.23

34,883,051

3

To approve the Directors' Remuneration Policy

7,728,166,817

98.19

142,531,194

1.81

7,870,698,011

85.23

35,150,085

4

To declare a final dividend

7,881,354,609

99.84

12,563,481

0.16

7,893,918,090

85.48

11,958,174

5

To re-appoint Sir Dave Lewis

7,876,931,973

99.79

16,601,260

0.21

7,893,533,233

85.48

12,312,579

6

To re-appoint Brian McNamara

7,871,084,400

99.72

22,088,009

0.28

7,893,172,409

85.47

12,708,193

7

To re-appoint Tobias Hestler

7,866,797,285

99.67

26,254,733

0.33

7,893,052,018

85.47

12,786,833

8

To re-appoint Vindi Banga

7,867,335,102

99.67

26,175,768

0.33

7,893,510,870

85.48

12,336,941

9

To re-appoint Marie-Anne Aymerich

7,890,512,208

99.96

3,112,405

0.04

7,893,624,613

85.48

12,221,032

10

To re-appoint Tracy Clarke

7,865,519,126

99.64

28,102,790

0.36

7,893,621,916

85.48

12,223,729

11

To re-appoint Dame Vivienne Cox

7,867,915,608

99.67

25,707,980

0.33

7,893,623,588

85.48

12,222,787

12

To re-appoint Asmita Dubey

7,888,796,930

99.94

4,631,311

0.06

7,893,428,241

85.48

12,314,510

13

To re-appoint Deirdre Mahlan

7,855,947,958

99.52

37,606,999

0.48

7,893,554,957

85.48

12,290,655

14

To re-appoint David Denton

7,756,457,683

98.27

136,511,465

1.73

7,892,969,148

85.47

12,872,307

15

To re-appoint Bryan Supran

7,870,491,722

99.72

22,373,713

0.28

7,892,865,435

85.47

12,981,360

16

To appoint KPMG LLP as Auditor of the Company

7,887,876,048

99.92

6,610,659

0.08

7,894,486,707

85.49

11,357,094

17

To authorise the Audit & Risk Committee to set the Auditor's remuneration

7,875,138,402

99.77

18,463,151

0.23

7,893,601,553

85.48

12,247,103

18

To authorise the Company to make political donations

7,811,060,234

99.39

48,180,724

0.61

7,859,240,958

85.11

46,594,903

19

To authorise the Directors to allot shares

7,730,625,212

97.95

161,493,695

2.05

7,892,118,907

85.46

13,723,569

20

General authority to disapply pre-emption rights

 

7,808,260,233

99.20

63,131,891

0.80

7,871,392,124

85.24

34,452,867

21

Additional authority to disapply pre-emption rights

 

7,771,569,791

98.73

99,828,862

1.27

7,871,398,653

85.24

34,442,507

22

To shorten the notice period for General Meetings

7,681,982,554

97.55

192,963,273

2.45

7,874,945,827

85.28

30,905,583

23

Approve the Performance Share Plan 2023 Rules

7,797,546,898

98.82

93,471,605

1.18

7,891,018,503

85.45

14,811,682

24

Approve the Share Value Plan 2023 Rules

7,828,310,178

99.20

62,943,305

0.80

7,891,253,483

85.45

14,570,255

25

Approve the Deferred Annual Bonus Plan 2023 Rules

7,831,723,780

99.25

58,910,350

0.75

7,890,634,130

85.45

15,186,161

26

To authorise the Company to purchase its own shares

7,878,575,931

99.82

14,281,790

0.18

7,892,857,721

85.47

12,988,792

27

To authorise the Company to make off-market purchases of its own shares from Pfizer3

4,928,538,385

99.87

6,306,129

0.13

4,934,844,514

53.44

15,940,710

28

To authorise the Company to make off-market purchases of its own shares from the GSK Shareholders4

6,688,398,038

99.91

6,123,957

0.09

6,694,521,995

72.49

16,004,606

29

Approval of waiver of Rule 9 Offer obligation5

4,768,473,630

97.47

123,562,632

2.53

4,892,036,262

52.98

58,740,625

 

1 For the purposes of section 341 of the Companies Act 2006, Haleon plc's total issued share capital with voting rights as at 6.30pm on 18 April 2023, being the time at which a shareholder had to be registered in the Company's register of members in order to attend and vote at the AGM, was 9,234,573,831.

 

2 A "Vote withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

3 Pfizer has agreed not to vote any of the Ordinary shares held in respect of Resolution 27.

4 The GSK Shareholders, as defined on page 25 of the Notice of Meeting, have agreed not to vote any of the Ordinary shares held in respect of Resolution 28.

5 Pfizer and any person acting in concert with Pfizer are precluded from voting on Resolution 29.

 

 

 

 

 

 

Haleon plc - Poll Results by Independent Shareholders

 

Resolution

Votes For

For (% of shares voted)

Votes Against

Against (% of shares voted)

Total Votes Cast (excluding withheld)

% of issued share capital voted1

Votes Withheld2

8

To re-appoint Vindi Banga

4,912,225,248

99.47

26,175,768

0.53

4,938,401,016

78.64%

12,336,941

9

To re-appoint Marie-Anne Aymerich

4,935,402,354

99.94

3,112,405

0.06

4,938,514,759

78.65%

12,221,032

10

To re-appoint Tracy Clarke

4,910,409,272

99.43

28,102,790

0.57

4,938,512,062

78.65%

12,223,729

11

To re-appoint Dame Vivienne Cox

4,912,805,754

99.48

25,707,980

0.52

4,938,513,734

78.65%

12,222,787

12

To re-appoint Asmita Dubey

4,933,687,076

99.91

4,631,311

0.09

4,938,318,387

78.64%

12,314,510

13

To re-appoint Deirdre Mahlan

4,900,838,104

99.24

37,606,999

0.76

4,938,445,103

78.64%

12,290,655

 

1 Percentage of votes cast by independent shareholders for Resolutions 8, 9, 10, 11, 12 and 13 appointing Independent Non-Executive Directors exclude Pfizer's 2,955,113,626 shares.

2 A "Vote withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

As required by the Listing Rule 9.6.2R of the Financial Conduct Authority ("FCA"), copies of resolutions passed by the Company other than resolutions concerning ordinary business have been submitted to the FCA via the National Storage Mechanism and will shortly be available to the public for inspection at  https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

 

Amanda Mellor 

Company Secretary 

 

 

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMQBLFLXZLLBBK
Date   Source Headline
17th May 20245:30 pmRNSHaleon
8th May 20245:15 pmRNSResults of Haleon 2024 Annual General Meeting
7th May 20249:30 amRNSEMTN programme: publication of base prospectus
1st May 202411:10 amRNSDirectorate Change
1st May 20247:00 amRNSHaleon 2024 Q1 Trading Statement
24th Apr 20247:00 amRNSAppointment of Dawn Allen as CFO
12th Apr 202412:00 pmRNSNotice of Annual General Meeting (AGM)
3rd Apr 202411:30 amRNSDirector/PDMR Shareholding
2nd Apr 20249:15 amRNSTotal Voting Rights and Capital
22nd Mar 202411:30 amRNSHolding(s) in Company
21st Mar 20246:00 pmRNSHaleon
21st Mar 20244:38 pmRNSTotal Voting Rights and Capital
21st Mar 20244:05 pmRNSClosing of Secondary Global Offering by Pfizer
20th Mar 20248:39 amRNSFinal prospectus supplement filed with the SEC
19th Mar 20247:00 amRNSPricing and upsize of Secondary Global Offering
18th Mar 202411:00 amRNSPreliminary prospectus supplement filed with SEC
18th Mar 20247:00 amRNSProposed Secondary Global Offering by Pfizer Inc.
15th Mar 20243:00 pmRNSPublication of Annual Report and Form 20-F 2023
14th Mar 20244:20 pmRNSDirector/PDMR Shareholding
12th Mar 20243:30 pmRNSDirector/PDMR Shareholding
5th Mar 20242:30 pmRNSDirector/PDMR Shareholding
29th Feb 20247:00 amRNSHaleon Preliminary 2023 Full Year Results
2nd Feb 20242:15 pmRNSDirector Declaration
25th Jan 20247:00 amRNSHaleon to sell ChapStick
18th Jan 20245:00 pmRNSHolding(s) in Company
17th Jan 20246:00 pmRNSHaleon
11th Jan 20241:00 pmRNSDirector/PDMR Shareholding
19th Dec 20231:00 pmRNSDirector/PDMR Shareholding
13th Dec 202310:30 amRNSDirector/PDMR Shareholding
10th Nov 20231:00 pmRNSDirector/PDMR Shareholding
2nd Nov 20237:00 amRNSHaleon 2023 Q3 Trading Statement
13th Oct 20233:30 pmRNSDirector/PDMR Shareholding
11th Oct 20233:00 pmRNSDirector/PDMR Shareholding
10th Oct 202311:00 amRNSHolding(s) in Company
6th Oct 20236:00 pmRNSHaleon
6th Oct 20232:30 pmRNSDirector/PDMR Shareholding
28th Sep 202311:00 amRNSDirector Declaration
13th Sep 20239:30 amRNSDirector/PDMR Shareholding
10th Aug 20231:00 pmRNSDirector/PDMR Shareholding
2nd Aug 20237:00 amRNSHaleon Half Year Results 2023
13th Jul 202311:00 amRNSDirector/PDMR Shareholding
12th Jun 20231:00 pmRNSDirector/PDMR Shareholding
16th May 20232:00 pmRNSHolding(s) in Company
16th May 20232:00 pmRNSHolding(s) in Company
12th May 20235:30 pmRNSHaleon
12th May 20234:30 pmRNSDirector/PDMR Shareholding
12th May 20239:30 amRNSEMTN programme publication of base prospectus
9th May 20235:00 pmRNSDirector/PDMR Shareholding
3rd May 20237:00 amRNS2023 Q1 Trading Statement
2nd May 20234:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.